SWTX Relative Valuation
SWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SWTX is overvalued; if below, it's undervalued.
Historical Valuation
SpringWorks Therapeutics Inc (SWTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.27 is considered Undervalued compared with the five-year average of -15.96. The fair price of SpringWorks Therapeutics Inc (SWTX) is between 335.66 to 345.03 according to relative valuation methord. Compared to the current price of 46.98 USD , SpringWorks Therapeutics Inc is Undervalued By 86%.
Relative Value
Fair Zone
335.66-345.03
Current Price：46.98
86%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
8.40
P/B
Median3y
4.63
Median5y
5.57
-4.80
FCF Yield
Median3y
-9.40
Median5y
-6.92
Competitors Valuation Multiple
The average P/S ratio for SWTX's competitors is 259.40, providing a benchmark for relative valuation. SpringWorks Therapeutics Inc Corp (SWTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 133.68%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is SpringWorks Therapeutics Inc (SWTX) currently overvalued or undervalued?
What is SpringWorks Therapeutics Inc (SWTX) fair value?
How does SWTX's valuation metrics compare to the industry average?
What is the current P/B ratio for SpringWorks Therapeutics Inc (SWTX) as of Jul 08 2025?
What is the current FCF Yield for SpringWorks Therapeutics Inc (SWTX) as of Jul 08 2025?
What is the current Forward P/E ratio for SpringWorks Therapeutics Inc (SWTX) as of Jul 08 2025?